Clinical development of targeted and immune based anti-cancer therapies
NA Seebacher, AE Stacy, GM Porter… - Journal of Experimental & …, 2019 - Springer
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
Ten things you should know about protein kinases: IUPHAR R eview 14
D Fabbro, SW Cowan‐Jacob… - British journal of …, 2015 - Wiley Online Library
Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
BR Lanning, LR Whitby, MM Dix, J Douhan… - Nature chemical …, 2014 - nature.com
Kinases are principal components of signal transduction pathways and the focus of intense
basic and drug discovery research. Irreversible inhibitors that covalently modify non-catalytic …
basic and drug discovery research. Irreversible inhibitors that covalently modify non-catalytic …
A simple method for developing lysine targeted covalent protein reagents
R Gabizon, B Tivon, RN Reddi… - Nature …, 2023 - nature.com
Peptide-based covalent probes can target shallow protein surfaces not typically addressable
using small molecules, yet there is a need for versatile approaches to convert native peptide …
using small molecules, yet there is a need for versatile approaches to convert native peptide …
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
M Takeda, K Nakagawa - International journal of molecular sciences, 2019 - mdpi.com
Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …
[HTML][HTML] Molecular pathways and therapeutic targets in lung cancer
E Shtivelman, T Hensing, GR Simon, PA Dennis… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma
T Nakaoku, K Tsuta, H Ichikawa, K Shiraishi… - Clinical cancer …, 2014 - AACR
Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma
(IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations …
(IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations …